Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma Corporation (ABUS)
NASDAQ:ABUS
Arbutus Biopharma (ABUS) Stock Price & Analysis
1,106 Followers
ABUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.85 - $3.15
Previous Close$2.5
Volume453.32K
Average Volume (3M)861.53K
Market Cap
$415.33M
Enterprise Value$270.72M
Total Cash (Recent Filing)$146.73M
Total Debt (Recent Filing)$2.12M
Price to Earnings (P/E)-5.5
Beta0.56
Next Earnings
Aug 03, 2023EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding166,133,563
10 Day Avg. Volume531,768
30 Day Avg. Volume861,534
Standard Deviation0.29
R-Squared0.17
Alpha0.00538
Financial Highlights & Ratios
Price to Book (P/B)2.91
Price to Sales (P/S)75.39
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.47
Enterprise Value/Gross Profit6.94
Enterprise Value/Ebitda-3.89
Forecast
1Y Price Target
$5.33Price Target Upside113.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Arbutus Biopharma News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABUS FAQ
What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest stock price was $1.85 and its highest was $3.15 in the past 12 months.
What is Arbutus Biopharma Corporation’s market cap?
Currently, no data Available
When is Arbutus Biopharma Corporation’s upcoming earnings report date?
Arbutus Biopharma Corporation’s upcoming earnings report date is Aug 03, 2023 which is in 66 days.
How were Arbutus Biopharma Corporation’s earnings last quarter?
Arbutus Biopharma Corporation released its earnings results on May 04, 2023. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.036.
Is Arbutus Biopharma Corporation overvalued?
According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued.
Does Arbutus Biopharma Corporation pay dividends?
Arbutus Biopharma Corporation does not currently pay dividends.
What is Arbutus Biopharma Corporation’s EPS estimate?
Arbutus Biopharma Corporation’s EPS estimate is -$0.11.
How many shares outstanding does Arbutus Biopharma Corporation have?
Arbutus Biopharma Corporation has 166,133,560 shares outstanding.
What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
Arbutus Biopharma Corporation reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went up 1.594%.
Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
Among the largest hedge funds holding Arbutus Biopharma Corporation’s share is Woodline Partners LP. It holds Arbutus Biopharma Corporation’s shares valued at 8M.
---
Arbutus Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.33 (113.20% Upside)
$5.33 (113.20% Upside)
Blogger Sentiment
Bullish
ABUS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.22%
12-Months-Change
Fundamentals
Return on Equity
-45.22%
Trailing 12-Months
Asset Growth
-19.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arbutus Biopharma Corporation
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
---
Top 5 ETFs holding ABUS
iShares Core S&P Total U.S. Stock Market ETF
$284.96K
iShares NASDAQ US Biotechnology UCITS ETF
$182.72K
iShares Russell 3000 ETF
$119.82K
Invesco Nasdaq Biotechnology ETF
$7.67K
Up to five ETFs with an Outperform Smart Score that hold ABUS. The ETFs are listed according to market value of ABUS within the ETF
---
Nkarta
―
Scholar Rock Holding
―
C4 Therapeutics
―
Lexicon Pharmaceuticals
―
Poseida Therapeutics
―
---